Most Read Articles
Natalia Reoutova, 02 Sep 2020

Combination immunotherapy with nivolumab (1 mg/kg) and high-dose ipilimumab (3 mg/kg), given every 3 weeks (nivo1+ipi3 Q3W) for four cycles, followed by flat-dose nivolumab (240 mg) maintenance every 2 weeks (Q2W), achieved greater efficacy vs two high-dose nivolumab (3 mg/kg) and ipilimumab (1 mg/kg) regimens (nivo3+ipi1) in patients with advanced hepatocellular carcinoma (HCC) and in Asian patients, in particular, according to a subanalysis of the phase I/II CheckMate 040 trial presented at the virtual World Congress on Gastrointestinal Cancer (WCGC) 2020.

Stephen Padilla, 03 Sep 2020
Real-world systemic sequential therapy with regorafenib confers survival benefits in patients with advanced hepatocellular carcinoma (HCC) who failed first-line sorafenib, consistent with previous clinical trial, according to a study in Korea.
2 days ago
A recent study has found no significant impact of 5α-reductase inhibitors on Gleason grading, with no difference in mortality seen among users and nonusers in each Gleason group.
12 Jun 2020
Drawing from experience as a key investigator in landmark clinical trials (including PALOMA, MONALEESA and MONARCH), and his clinical experience with CDK4/6 inhibitors, Dr Rafael Villanueva Vázquez shares his insights into the current evidence of using CDK4/6 inhibitors to treat HR+/HER2- ABC.

Eating right boosts breast cancer survival

2 days ago

Following an anti-inflammatory approach to diet following breast cancer diagnosis helps improves the outlook of patients, with its protective effects increasing over the long term, a study reports.

The analysis included 1,064 female breast cancer survivors in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening (PLCO) Trial prospective cohort, all of whom had completed the diet history questionnaire (DHQ).

Researchers calculated energy-adjusted dietary inflammatory index (E-DII) scores based on food and supplement intake, with higher scores indicating more pro-inflammatory diets and lower (ie, more negative) scores indicating more anti-inflammatory diets.

At baseline, patients consuming the most pro-inflammatory diets (ie, −4.1 to 4.9, E-DII tertile 3) had a higher total energy intake, higher body mass index, and more current hormone therapy, among others.

Over a median follow-up of 14.6 years, 296 (27.8 percent) all-cause and 100 (9.4 percent) breast cancer-specific deaths were recorded. Cox regression analysis revealed that consuming the most pro-inflammatory diets conferred increased risks of all-cause mortality (E-DII scores tertile 3 vs 1: hazard ratio [HR], 1.34, 95 percent confidence interval [CI], 1.01–1.81; ptrend=0.049) and breast cancer mortality (tertile 3 vs 1: HR, 1.47, 95 percent CI, 0.89–2.43; ptrend=0.13).

Each 1-unit increment in E-DII score was associated with a 6-percent increase in all-cause mortality risk (HR, 1.06, 95 percent CI, 1.00–1.13) and a 10-percent increase in breast cancer mortality (HR, 1.10, 95 percent CI, 1.00–1.22).

The findings highlight the potential of adopting anti-inflammatory diets after diagnosis as a means for reducing risk of breast cancer-specific and all-causes death among survivors, the researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Natalia Reoutova, 02 Sep 2020

Combination immunotherapy with nivolumab (1 mg/kg) and high-dose ipilimumab (3 mg/kg), given every 3 weeks (nivo1+ipi3 Q3W) for four cycles, followed by flat-dose nivolumab (240 mg) maintenance every 2 weeks (Q2W), achieved greater efficacy vs two high-dose nivolumab (3 mg/kg) and ipilimumab (1 mg/kg) regimens (nivo3+ipi1) in patients with advanced hepatocellular carcinoma (HCC) and in Asian patients, in particular, according to a subanalysis of the phase I/II CheckMate 040 trial presented at the virtual World Congress on Gastrointestinal Cancer (WCGC) 2020.

Stephen Padilla, 03 Sep 2020
Real-world systemic sequential therapy with regorafenib confers survival benefits in patients with advanced hepatocellular carcinoma (HCC) who failed first-line sorafenib, consistent with previous clinical trial, according to a study in Korea.
2 days ago
A recent study has found no significant impact of 5α-reductase inhibitors on Gleason grading, with no difference in mortality seen among users and nonusers in each Gleason group.
12 Jun 2020
Drawing from experience as a key investigator in landmark clinical trials (including PALOMA, MONALEESA and MONARCH), and his clinical experience with CDK4/6 inhibitors, Dr Rafael Villanueva Vázquez shares his insights into the current evidence of using CDK4/6 inhibitors to treat HR+/HER2- ABC.